The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021

Paolo A. Ascierto*, Lisa H. Butterfield, Olivera J. Finn, Andrew Futreal, Omid Hamid, Theresa LaVallee, Michael A. Postow, Igor Puzanov, Jeffrey Sosman, Bernard A. Fox, Patrick Hwu

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

As part of the 2021 Immunotherapy Bridge virtual congress (December 1–2, Naples, Italy), the Great Debate sessions featured experts who were assigned counter opposing views on four important questions in immunotherapy today. The first topic was whether oncolytic viruses or other specific immunomodulators were the more promising approach for intralesional therapy. The second was whether early surrogate endpoints, such as response rate or progression-free survival, correlate with long-term overall survival was considered. Thirdly, whether vaccines can transform cold into hot tumors was discussed and, finally, broad versus deep analytic profiling approaches to gain insights into immune-oncology development were compared. As with previous Bridge congresses, presenters were invited by the meeting Chairs and positions taken during the debates may not have reflected their respective personal view. In addition, the views summarised in this article are based on available evidence but may reflect personal interpretation of these data, clinical experience and subjective opinion of the speaker.

Original languageEnglish (US)
Article number179
JournalJournal of Translational Medicine
Volume20
Issue number1
DOIs
StatePublished - Dec 2022

Keywords

  • Cancer vaccine
  • Checkpoint inhibitors
  • Clinical trials
  • Immunotherapy
  • Nivolumab
  • Overall survival
  • Pembrolizumab
  • Progression-free survival

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021'. Together they form a unique fingerprint.

Cite this